In a phase I clinical study (UMIN000001395), GPC3-derived peptide vaccine was used in 33 patients with advanced HCC and reported that vaccination was well-tolerated, inducing a high rate of GPC3-specific CTL response [93]. Here, GPC3 is linked to hepatocellular carcinoma.